Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199270 | 0.94 | MAOB (0.52) | MAOBMAOAHRH3ADRA1DADRA1A | |
| SCHEMBL29097941 | 0.94 | MAOB (0.52) | MAOBMAOAHRH3ADRA1DADRA1A | |
| SCHEMBL566484 | 0.86 | MAOB (0.56) | MAOBMAOAHRH3CD274 | |
| SCHEMBL1020646 | 0.86 | CD274 (0.61) | MAOBMAOAHRH3CD274CYP2D6 | |
| SCHEMBL27928328 | 0.85 | CD274 (0.47) | MAOBMAOAHRH3CD274ADRA2A | |
| SCHEMBL29097880 | 0.81 | MAOB (0.56) | MAOBMAOAHRH3CD274 | |
| SCHEMBL30199170 | 0.81 | MAOB (0.56) | MAOBMAOAHRH3CD274 | |
| SCHEMBL30199477 | 0.81 | PNMT (0.58) | MAOBMAOAHRH3ADRA2AADRA2B | |
| SCHEMBL30199572 | 0.81 | PNMT (0.58) | MAOBMAOAHRH3CD274ADRA2A | |
| SCHEMBL3876596 | 0.81 | PNMT (0.58) | MAOBMAOAHRH3ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1844045-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1501804-A1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091219-A1 | ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | MAOB 383/4885MAOA 726/4885HRH3 325/4885 |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | MAOB 1/4885MAOA 2/4885HRH3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.